Signed, SEALed, detected I’m your patient with advanced fibrosis or cirrhosis!

SEAL: Why was this approach not effective?

“…The recently launched EASL-Lancet Liver Commission is aimed at increasing liver health awareness and reducing liver-associated mortality (6) . Yet it remains to be clarified whether increasing liver health awareness and early identification of patients with cACLD leads to a reduction in liver associated mortality (7). Nevertheless, measures which lead to an increase in survival in patients with compensated cirrhosis and clinically significant portal hypertension have been recently reported (8).…”